Vascular disrupting agents: A new class of drug in cancer therapy

Clinical Oncology

Volumn 17, Issue 4, 2005, Pages 277-290

  Gaya, Andrew M ^a   Rustin, J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Angiogenesis; Combretastatin; DCE MRI; DMXAA; Vascular targeting; ZD6126

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURISTATIN PE; AVE 8062A; CISPLATIN; COLCHICINE; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CYTOKINE; DOCETAXEL; DOLASTATIN; DOLASTATIN 10; DOXORUBICIN; DURAMYCIN IMMUNOGLOBULIN G CONJUGATE; FLAVONOID; FLUOROURACIL; HYDRALAZINE; IRINOTECAN; MITOFLAXONE; MN 029; MONOCLONAL ANTIBODY 3G4; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN GELONIN CONJUGATE; VINBLASTINE;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ATAXIA; BONE MARROW SUPPRESSION; BRADYCARDIA; BREAST CARCINOMA; BYSTANDER EFFECT; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PAIN; CANCER RESISTANCE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; DIARRHEA; DIPLOPIA; DOSE RESPONSE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; EYE TOXICITY; FATIGUE; FLUSHING; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INTRACRANIAL HYPERTENSION; MALAISE; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; SENSORIMOTOR NEUROPATHY; SEROTONIN SYNDROME; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TREMOR; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION; URINE INCONTINENCE; VISUAL DISORDER; VISUAL IMPAIRMENT;

EID: 19344378137     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2004.11.011     Document Type: Article

References (135)

1. Vaupel P. Abnormal microvasculature and defective microcirculatory function in solid tumours [abstract 1]. Proc 2nd international conference on vascular targeting 2004.
2. D. Hanahan J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353-364
3. W. Risau Mechanisms of angiogenesis Nature 386 1997 671-674
4. S. Morikawa P. Baluk T. Kaidoh A. Haskell R.K. Jain D.M. McDonald Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160 2002 985-1000
5. H. Hashizume P. Baluk S. Morikawa et al. Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156 2000 1363-1380
6. D.M. McDonald P. Baluk Significance of blood vessel leakiness in cancer Cancer Res 62 2002 5381-5385
7. Y. Maeshima P.C. Colorado A. Torre et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane J Biol Chem 275 2000 21340-21348
8. B.C. Baguley Antivascular therapy of cancer: DMXAA Lancet Oncol 4 2003 141-188
9. C.O. Starnes Coley's toxins in perspective Nature 357 1992 11-12
10. T.F. Logan F. Jadali M.J. Egorin et al. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial Cancer Chemother Pharmacol 50 2002 433-444
11. N. Renard D. Lienard L. Lespagnard A. Eggermont R. Heimann F. Lejeune Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha) Int J Cancer 57 1994 656-663
12. S. Moncada E.A. Higgs Molecular mechanisms and therapeutic strategies related to nitric oxide FASEB J 9 1995 1319-1330
13. J. Denekamp Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy [review] Br J Radiol 66 1993 181-196
14. F.J. Burrows P.E. Thorpe Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature Proc Natl Acad Sci U S A 90 1993 8996-9000
15. S.A. Hill S.J. Lonergan J. Denekamp D.J. Chaplin Vinca alkaloids: anti-vascular effects in a murine tumour Eur J Cancer 29A 1993 1320-1324
16. G.M. Tozer C. Kanthou C.S. Parkins S.A. Hill The biology of the combretastatins as tumour vascular targeting agents Int J Exp Pathol 83 2002 21-38
17. X. Huang G. Molema S. King L. Watkins T.S. Edgington P.E. Thorpe Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature Science 275 1997 547-550
18. D.C. Blakey F.R. Westwood M. Walker et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models Clin Cancer Res 8 2002 1974-1983
19. L.M. Ching D. Goldsmith W.R. Joseph H. Korner J.D. Sedgwick B.C. Baguley Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice Cancer Res 59 1999 3304-3307
20. P.E. Thorpe D.J. Chaplin D.C. Blakey The first international conference on vascular targeting: Meeting overview Cancer Res 63 2003 1144-1147
21. T. Boehm J. Folkman T. Browder M.S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404-407
22. J. Griggs J.C. Metcalfe R. Hesketh Targeting tumour vasculature: The development of combretastatin A4 Lancet Oncol 2 2001 82-87
23. D.M. McDonald L. Munn R.K. Jain Vasculogenic mimicry: How convincing, how novel, and how significant? Am J Pathol 156 2000 383-388
24. A.J. Maniotis R. Folberg A. Hess et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry Am J Pathol 155 1999 739-752
25. R. Folberg M.J. Hendrix A.J. Maniotis Vasculogenic mimicry and tumor angiogenesis Am J Pathol 156 2000 361-381
26. D.J. Chaplin M.R. Horsman The influence of tumour temperature on ischemia-induced cell death: Potential implications for the evaluation of vascular mediated therapies Radiother Oncol 30 1994 59-65
27. P.E. Thorpe Vascular targeting agents as cancer therapeutics Clin Cancer Res 10 2004 415-427
28. R. Pasqualini W. Arap Translation of vascular diversity into targeted therapeutics Ann Hematol 81 suppl 2 2002 S66-S67
29. M. Trepel W. Arap R. Pasqualini Exploring vascular heterogeneity for gene therapy targeting Gene Ther 7 2000 2059-2060
30. F. Nilsson H. Kosmehl L. Zardi D. Neri Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice Cancer Res 61 2001 711-716
31. X. Huang M. B J. He L. Watkins P. Thorpe Anti-phosphatidylserine monoclonal antibody 3G4 enhances the anti tumour effects of docetaxel against human breast carcinoma [abstract 1498] Proc Am Assoc Cancer Res 45 2004
32. He JS, Li Thorpe P. Duramycin-IgG conjugate targeted to phosphatidylethanolamine on tumour blood vessels [abstract]. Proc 2nd international conference on vascular targeting 2004;2t.
33. W. Arap M.G. Kolonin M. Trepel et al. Steps toward mapping the human vasculature by phage display Nat Med 8 2002 121-127
34. G.P. Smith S.B. Calveley M.J. Smith B.C. Baguley Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours [abstract 1498] Eur J Cancer Clin Oncol 23 1987 1209-1211
35. T.H. Corbett M.C. Bissery A. Wozniak et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice Invest New Drugs 4 1986 207-220
36. D.J. Kerr S.B. Kaye Flavone acetic acid - preclinical and clinical activity Eur J Cancer Clin Oncol 25 1989 1271-1272
37. G.W. Rewcastle G.J. Atwell Z.A. Li B.C. Baguley W.A. Denny Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids J Med Chem 34 1991 217-222
38. C.J. Lash A.E. Li M. Rutland B.C. Baguley L.J. Zwi W.R. Wilson Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs Br J Cancer 78 1998 439-445
39. L.M. Ching Z. Cao C. Kieda S. Zwain M.B. Jameson B.C. Baguley Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid Br J Cancer 86 2002 1937-1942
40. B.C. Baguley L. Zhuang P. Kestell Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects Oncol Res 9 1997 55-60
41. L.L. Thomsen L.M. Ching L. Zhuang J.B. Gavin B.C. Baguley Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice Cancer Res 51 1991 77-81
42. M. Philpott L.M. Ching B.C. Baguley The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor Eur J Cancer 37 2001 1930-1937
43. L.J. Zwi B.C. Baguley J.B. Gavin W.R. Wilson Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents Oncol Res 6 1994 79-85
44. A. Yilmaz G. Bieler O. Spertini F.J. Lejeune C. Ruegg Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology Int J Cancer 77 1998 592-599
45. K. Norioka E.C. Borden R. Auerbach Inhibitory effects of cytokines on vascular endothelial cells: Synergistic interactions among interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 J Immunother 12 1992 13-18
46. V. Mahadevan S.T. Malik A. Meager W. Fiers G.P. Lewis I.R. Hart Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown Cancer Res 50 1990 5537-5542
47. E. Moilanen L.L. Thomsen D.W. Miles D.W. Happerfield R.G. Knowles S. Moncada Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid Br J Cancer 77 1998 426-433
48. M.B. Jameson P.I. Thompson B.C. Baguley et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent Br J Cancer 88 2003 1844-1850
49. G.J. Rustin C. Bradley S. Galbraith 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study Br J Cancer 88 2003 1160-1167
50. M. Jameson P. Thompson B. Baguley et al. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel anti vascular agent [abstract 705] Proc Am Soc Clin Oncol 2000
51. S.M. Galbraith G.J. Rustin M.A. Lodge et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 2002 3826-3840
52. S. Cliffe M.L. Taylor M. Rutland B.C. Baguley R.P. Hill W.R. Wilson Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid Int J Radiat Oncol Biol Phys 29 1994 373-377
53. F.B. Pruijn M. van Daalen N.H. Holford W.R. Wilson Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid Cancer Chemother Pharmacol 39 1997 541-546
54. W.R. Wilson A.E. Li D.S. Cowan B.G. Siim Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid Int J Radiat Oncol Biol Phys 42 1998 905-908
55. R.B. Pedley J.A. Boden R. Boden et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents Cancer Res 56 1996 3293-3300
56. R.B. Pedley S.K. Sharma G.M. Boxer et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent Cancer Res 59 1999 3998-4003
57. D.J. Chaplin G.R. Pettit C.S. Parkins S.A. Hill Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents Br J Cancer Suppl 27 1996 S86-S88
58. J. Griggs R. Hesketh G.A. Smith et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue Br J Cancer 84 2001 832-835
59. S.M. Galbraith D.J. Chaplin F. Lee et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo Anticancer Res 21 2001 93-102
60. D.J. Chaplin G.J. Dougherty Tumour vasculature as a target for cancer therapy Br J Cancer 80 suppl 1 1999 57-64
61. C.M. Lin H.H. Ho G.R. Pettit E. Hamel Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 28 1989 6984-6991
62. G.R. Pettit C. Temple Jr. V.L. Narayanan et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs Anticancer Drug Des 10 1995 299-309
63. G.R. Pettit S.B. Singh E. Hamel C.M. Lin D.S. Alberts D. Garcia-Kendall Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 45 1989 209-211
64. S. Iyer D.J. Chaplin D.S. Rosenthal A.H. Boulares L.Y. Li M.E. Smulson Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4 Cancer Res 58 1998 4510-4514
65. C. Kanthou G.M. Tozer The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood 99 2002 2060-2069
66. S.A. Hill G.M. Tozer G.R. Pettit D. Chaplin Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi4503 Anticancer Res 22 2002 1453-1458
67. D.J. Chaplin G.R. Pettit S.A. Hill Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate Anticancer Res 19 1999 189-195
68. K. Grosios S.E. Holwell A.T. McGown G.R. Pettit M.C. Bibby In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug Br J Cancer 81 1999 1318-1327
69. K. Grosios P.M. Loadman D.J. Swaine G.R. Pettit M.C. Bibby Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma Anticancer Res 20 2000 229-233
70. G.G. Dark S.A. Hill V.E. Prise G.M. Tozer G.R. Pettit D.J. Chaplin Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1997 1829-1834
71. M.R. Horsman E. Ehrnrooth M. Ladekarl J. Overgaard The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors Int J Radiat Oncol Biol Phys 42 1998 895-898
72. G.M. Tozer V.E. Prise J. Wilson et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability Cancer Res 61 2001 6413-6422
73. D.A. Beauregard P.E. Thelwall D.J. Chaplin S.A. Hill G.E. Adams K.M. Brindle Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status Br J Cancer 77 1998 1761-1767
74. G.M. Tozer V.E. Prise J. Wilson R.J. Locke et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues Cancer Res 59 1999 1626-1634
75. G.M. Tozer K.M. Shaffi Modification of tumour blood flow using the hypertensive agent, angiotensin II Br J Cancer 67 1993 981-988
76. M.R. Horsman K.L. Christensen J. Overgaard Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure Int J Radiat Oncol Biol Phys 22 1992 455-458
77. H.L. Anderson J.T. Yap M.P. Miller A. Robbins T. Jones P.M. Price Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 2003 2823-2830
78. A. Dowlati K. Robertson M. Cooney et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 2002 3408-3416
79. E. Guatteo L. Bianchi L. Faravelli et al. A novel K+ channel blocker isolated from 'hiccup nut' toxin Neuroreport 7 1996 2575-2579
80. G.J. Rustin S.M. Galbraith H. Anderson et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results J Clin Oncol 21 2003 2815-2822
81. S.M. Galbraith R.J. Maxwell M.A. Lodge et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2003 2831-2842
82. R. Simon B. Freidlin L. Rubinstein S.G. Arbuck J. Collins M.C. Christian Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1997 1138-1147
83. J.P. Stevenson M. Rosen W. Sun et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow J Clin Oncol 21 2003 4428-4438
84. M.P. Bevilacqua R.M. Nelson Selectins J Clin Invest 91 1993 379-387
85. C. Ferri G. Desideri R. Baldoncini et al. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities Diabetes 47 1998 660-667
86. R.F. DeVore C.G. Hellerqvist G.B. Wakefield et al. Phase I study of the antineovascularization drug CM101 Clin Cancer Res 3 1997 365-672
87. D.C. Blakey S.E. Ashton F.R. Westwood M. Walker A.J. Ryan ZD6126: A novel small molecule vascular targeting agent Int J Radiat Oncol Biol Phys 54 2002 1497-1502
88. P.D. Davis G.J. Dougherty D.C. Blakey et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247-7253
89. M.R. Horsman R. Murata Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response Int J Radiat Oncol Biol Phys 57 2003 1047-1055
90. Anon Vascular targeting: Clinical experience In: Horizons inc cancer therapeutics: From bench to bedside 3 2002 Meniscus Philadelphia 16-23
91. S.M. Gadgeel P. LoRusso A.J. Wozniak C. Wheeler A dose escalation study of the novel vascular targeting agent ZD6126 in patients with solid tumours [abstract 438] Proc Am Soc Clin Oncol 21 2002
92. S. LoRusso S. Gadgeel A. Wozniak et al. A phase I dose escalation trial of ZD6126, a novel vascular targeting agent, in patients with cancer refractory to other treatments [abstract 36] Proc AACR-NCI-EORTC 2001
93. Z. DelProposto P. LoRusso Z Latif et al. MRI evaluation of the effects of the vascular targeting agent ZD6126 on tumor vasculature [abstract 440] Proc Am Soc Clin Oncol 21 2002
94. S.A. Radema L. Beerepoot P.O. Witteveen et al. Clinical evaluation of the novel vascular targeting agent ZD6126: Assessment of toxicity and surrogate markers of vascular damage [abstract 439] Proc Am Soc Clin Oncol 21 2002
95. K. Hori S. Saito Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis Br J Cancer 89 2003 1334-1344
96. K. Hori S. Saito Y. Nihei M. Suzuki Y. Sato Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700 Jpn J Cancer Res 90 1999 1026-1038
97. P. Lejeune T. H P. Vrignaud et al. In vivo antitumour activity and tumor necrosis induced by AVE8062A, a tumour vascular targeting agent [abstract 781] Proc Am Assoc Cancer Res 43 2002
98. A.W. Tolcher L. Forero P. Celio L.A. Hammond E.K. Rowinsky et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days [abstract 834] Proc Am Soc Clin Oncol 22 2003
99. Vrignaud P. In vivo synergy between cytotoxic agents and AVE8062A: A tumour vascular targeting agent [abstract 8]. Proc 2nd international conference on vascular targeting, Miami, Florida 2004.
100. T. Natsume Y. Koh M. Kobayashi Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo Cancer Chemother Pharmacol 49 2002 35-47
101. M. Otani T. Natsume J.I. Watanabe et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death Jpn J Cancer Res 91 2000 837-844
102. Palladino MN, Rena Bahjat B, Borgstrom F, Neuteboom P, Kenneth Lloyd STCG. NPI-2358: A novel diketopiperazine that induces tumour vascular collapse [abstract 19]. Proc 2nd international conference on vascular targeting, Miami, Florida 2004.
103. McCreedy BK, Locke T, K W. The novel vascular disrupting agent, MN-029, shows potent and selective anti-tumour activity in preclinical animal models [abstract 23]. Proc 2nd international conference on vascular targeting, Miami, Florida 2004.
104. A.R. Padhani J.E. Husband Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies Clin Radiol 56 2001 607-620
105. A.R. Padhani Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions J Magn Reson Imaging 16 2002 407-422
106. P.S. Tofts G. Brix D.L. Buckley et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols J Magn Reson Imaging 10 1999 223-232
107. S.M. Galbraith M.A. Lodge N.J. Taylor et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis NMR Biomed 15 2002 132-142
108. J.L.P. Evelhoch Z. Latif P. Morton et al. Reproducibility of dynamic contrast enhanced (DCE-MRI) assessment of tumor vascularity [abstract 399] Proc Am Soc Clin Oncol 20 2001
109. K.M. Donahue H.G. Krouwer S.D. Rand et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients Magn Reson Med 43 2000 845-853
110. R. Brasch K. Turetschek MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report Eur J Radiol 34 2000 148-155
111. H. Anderson P.M. Price Clinical measurement of blood flow in tumours using PET: A review Nucl Med Commun 23 2002 131-138
112. H. Wildiers B. Ahmed G. Guetens et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence Eur J Cancer 40 2004 284-290
113. B.D. Nelkin D.W. Ball Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma Oncol Rep 8 2001 157-160
114. L. Li A. Rojiani D.W. Siemann Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy Int J Radiat Oncol Biol Phys 42 1998 899-903
115. R.B. Pedley S.A. Hill G.M. Boxer et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate Cancer Res 61 2001 4716-4722
116. R.B. Pedley E. El-Emir A.A. Flynn et al. Synergy between vascular targeting agents and antibody-directed therapy Int J Radiat Oncol Biol Phys 54 2002 1524-1531
117. D.W. Siemann E. Mercer S. Lepler A.M. Rojiani Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 2002 1-6
118. H.N. Lode T. Moehler R. Xiang et al. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proc Natl Acad Sci U S A 96 1999 1591-1596
119. H.J. Mauceri N.N. Hanna M.A. Beckett et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287-291
120. M.R. Horsman R. Murata Combination of vascular targeting agents with thermal or radiation therapy Int J Radiat Oncol Biol Phys 54 2002 1518-1523
121. H.P. Eikesdal R. Bjerkvig O. Mella O. Dahl Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors Radiother Oncol 60 2001 147-154
122. D.W. Siemann A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 2002 164-171
123. D.W. Siemann W. Shi Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy Semin Radiat Oncol 13 2003 53-61
124. W. Landuyt B. Ahmed S. Nuyts et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment Int J Radiat Oncol Biol Phys 49 2001 443-450
125. R. Murata D.W. Siemann J. Overgaard M.R. Horsman Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid Radiat Res 156 2001 503-509
126. R. Murata J. Overgaard M.R. Horsman Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy Int J Radiat Oncol Biol Phys 51 2001 1018-1024
127. Lankester K, P B. Acute anti vascular effects of combretastatin A4 phosphate (CA4P) on The SW1222 tumour as measured by dynamic contrast enhanced MRI (DCE-MRI) 2004.
128. J.H. Bilenker J. Stevenson M.A. Rosen M. Gallagher et al. Phase Ib trial of combretastatin A4 phosphate (CA4P) in combination with carboplatin in patients with advanced cancer [abstract 889] Proc Am Soc Clin Oncol 2003 22
129. Siim B. The DMXAA experience [abstract 5]. Proc 2nd international conference on vascular targeting, Miami, Florida 2004.
130. D.W. Siemann Vascular targeting agents In: Horizons in cancer therapeutics: From bench to bedside 3 2002 Meniscus Philadelphia 4-15
131. S.R. Wedge J. Kendrew D.J. Ogilvie et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular targeting agent ZD6126 produces an enhanced anti-tumor response Proc Am Assoc Cancer Res 43 2002 1081
132. J. Griggs J.N. Skepper G.A. Smith K.M. Brindle J.C. Metcalfe R. Hesketh Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4 Am J Pathol 160 2002 1097-1103
133. S. Kakolyris S.B. Fox M. Koukourakis et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39 Br J Cancer 82 2000 844-851
134. P. Carmeliet R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249-257
135. Website NCI. http://www.cancer.gov/clinicaltrials/developments/ anti-angio-table.